Protecting the Cornea in Glaucoma: Why I Intervene Earlier with MIGS
Available from: 4/03/2026 (AEDT)
Where to publish: https://lms.optometry.org.au/course/view.php?id=988
Provider: Mivision
Activity Outline
One of the
most common things I hear from patients living with glaucoma is not that their
vision is deteriorating, nor that their pressures are too high – but that their
eyes are sore. Tired, red, gritty, uncomfortable eyes are part of the daily
lived experience for many people on long-term topical therapy. For some, this
discomfort has become so normalised that they no longer attribute it to their treatment.
Yet as clinicians, we notice the keratopathy, lid margin keratinisation,
meibomian gland dysfunction, conjunctival hyperaemia, and micropapillary
responses that silently accumulate across years of medical management. So, what
can we do to help these patients?
Learning Objectives
- Describe mechanisms by which chronic topical glaucoma therapies contribute to ocular surface disease,
- Explain the role of MIGS in reducing medication burden and improving long‑term outcomes, and
- Identify clinical scenarios appropriate for early MIGS referral within collaborative care.
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Protecting the Cornea in Glaucoma: Why I Intervene Earlier with MIGS |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |